Integra LifeSciences Holdings Resultados de beneficios anteriores
Pasado controles de criterios 1/6
Integra LifeSciences Holdings ha aumentado sus beneficios a una tasa media anual de 17%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 13.5% anual. Los ingresos han ido creciendo a una tasa media de 1.5% al año. La rentabilidad financiera de Integra LifeSciences Holdings es de 4.3%, y sus márgenes netos son de 4.4%.
Información clave
17.0%
Tasa de crecimiento de los beneficios
17.6%
Tasa de crecimiento del BPA
Crecimiento de la industria Medical Equipment | 8.9% |
Tasa de crecimiento de los ingresos | 1.5% |
Rentabilidad financiera | 4.3% |
Margen neto | 4.4% |
Próxima actualización de resultados | 06 May 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?
Oct 19We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Oct 05Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value
Sep 13Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 06FDA labels recall of intracranial pressure monitors by Integra as most serious
Aug 31Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance
Aug 24Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down
Aug 23Integra LifeSciences founder/former CEO dies
Aug 16Integra LifeSciences Holdings GAAP EPS of $0.54 beats by $0.09, revenue of $398M beats by $2.62M
Jul 27Is There An Opportunity With Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 47% Undervaluation?
Jul 20These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Jul 07Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Integra LifeSciences Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Dec 23 | 1,542 | 68 | 593 | 83 |
30 Sep 23 | 1,543 | 101 | 594 | 84 |
30 Jun 23 | 1,545 | 131 | 614 | 87 |
31 Mar 23 | 1,562 | 172 | 615 | 84 |
31 Dec 22 | 1,558 | 181 | 614 | 82 |
30 Sep 22 | 1,565 | 173 | 625 | 81 |
30 Jun 22 | 1,567 | 166 | 619 | 82 |
31 Mar 22 | 1,559 | 157 | 614 | 79 |
31 Dec 21 | 1,542 | 169 | 637 | 93 |
30 Sep 21 | 1,526 | 216 | 604 | 74 |
30 Jun 21 | 1,509 | 206 | 597 | 72 |
31 Mar 21 | 1,378 | 170 | 555 | 68 |
31 Dec 20 | 1,372 | 134 | 595 | 77 |
30 Sep 20 | 1,378 | 56 | 573 | 77 |
30 Jun 20 | 1,387 | -3 | 584 | 78 |
31 Mar 20 | 1,512 | 27 | 623 | 81 |
31 Dec 19 | 1,518 | 50 | 688 | 80 |
30 Sep 19 | 1,506 | 60 | 608 | 74 |
30 Jun 19 | 1,493 | 101 | 610 | 75 |
31 Mar 19 | 1,475 | 83 | 608 | 76 |
31 Dec 18 | 1,472 | 61 | 691 | 78 |
30 Sep 18 | 1,458 | 80 | 607 | 75 |
30 Jun 18 | 1,371 | 70 | 572 | 70 |
31 Mar 18 | 1,287 | 69 | 546 | 66 |
31 Dec 17 | 1,188 | 65 | 517 | 63 |
30 Sep 17 | 1,075 | 49 | 475 | 60 |
30 Jun 17 | 1,047 | 66 | 460 | 60 |
31 Mar 17 | 1,014 | 68 | 446 | 59 |
31 Dec 16 | 992 | 75 | 431 | 58 |
30 Sep 16 | 985 | 61 | 426 | 57 |
30 Jun 16 | 958 | 9 | 415 | 56 |
31 Mar 16 | 919 | 9 | 395 | 53 |
31 Dec 15 | 883 | 7 | 377 | 50 |
30 Sep 15 | 854 | 12 | 360 | 47 |
30 Jun 15 | 827 | 53 | 346 | 44 |
31 Mar 15 | 782 | 46 | 325 | 42 |
31 Dec 14 | 797 | 36 | 335 | 43 |
30 Sep 14 | 798 | 30 | 345 | 47 |
30 Jun 14 | 814 | -10 | 356 | 49 |
31 Mar 14 | 855 | -13 | 380 | 51 |
31 Dec 13 | 697 | 22 | 305 | 42 |
30 Sep 13 | 830 | -22 | 373 | 50 |
30 Jun 13 | 827 | 21 | 365 | 50 |
Ingresos de calidad: IART tiene un gran one-off loss de $147.7M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.
Margen de beneficios creciente: Los actuales márgenes de beneficio(4.4%) de IART son inferiores a los del año pasado (11.6%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de IART han crecido un 17% al año en los últimos 5 años.
Acelerando crecimiento: IART ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: IART tuvo un crecimiento negativo de los beneficios (-62.5%) durante el año pasado, lo que dificulta la comparación con la media de la industria Medical Equipment (3.3%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de IART (4.3%) se considera baja.